Khaled Greish1, Sebastien Taurin2, Mohamed A Morsy3,4. 1. Department of Molecular Medicine, Nanomedicine Unit, College of Medicine & Medical Sciences, Princess Al-Jawhara Center for Molecular Medicine, Arabian Gulf University, Manama 329, Bahrain. 2. Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, University of Utah Health Sciences, Salt Lake City, 84132, UT, USA. 3. Department of Pharmaceutical Sciences, College of Clinical Pharmacy, King Faisal University, 31982 Al-Ahsa, Saudi Arabia. 4. Department of Pharmacology, Faculty of Medicine, Minia University, 61511 El-Minia, Egypt.
Abstract
AIM: This study tested the effect of TNF-α, a cytokine associated with inflammation, and tumor progression, on enhancing doxorubicin (Dox) tumor accumulation, and improving its therapeutic effect. MATERIALS & METHODS: 4T1 murine breast cancer cells were injected into the flanks of Balb/c female mice and treated with TNF-α, Dox and a combination of both. RESULTS & CONCLUSION: The addition of TNF-α to Dox did not improve anticancer activity against 4T1 breast cancer cells in vitro. In 4T1 tumor-bearing mice, the pretreatment with TNF-α increased tumor Dox concentration. The accumulation of Dox was even higher when systemically injected with a micellar formulation of Dox. This work provides a rationale for testing the combination on breast cancer patients.
AIM: This study tested the effect of TNF-α, a cytokine associated with inflammation, and tumor progression, on enhancing doxorubicin (Dox) tumor accumulation, and improving its therapeutic effect. MATERIALS & METHODS: 4T1 murinebreast cancer cells were injected into the flanks of Balb/c female mice and treated with TNF-α, Dox and a combination of both. RESULTS & CONCLUSION: The addition of TNF-α to Dox did not improve anticancer activity against 4T1 breast cancer cells in vitro. In 4T1 tumor-bearing mice, the pretreatment with TNF-α increased tumorDox concentration. The accumulation of Dox was even higher when systemically injected with a micellar formulation of Dox. This work provides a rationale for testing the combination on breast cancerpatients.
Entities:
Keywords:
TNF-α; anticancer activity; doxorubicin; drug delivery; micelle